----
Current ValuationThe current P/E ratio is 60.49, above the reasonable range, cheaper than 19.94% of the time in the past 5 years, and the industry ranks 54/608, the industry Median -1.97.
60.49xP/E
$120.39Stock price
$1.99Earnings per share
60.49xP/E
Stock price$120.39Earnings per share$1.99
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 20.66x
- Typical range
- 16.59x–58.69x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
016324864
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
ONCUSBeigene | 64.20x | 199.66% | $42.09B |
INCYUSIncyte | 60.49x | 66.20% | $24.40B |
KNSAUSKiniksa Pharmaceuticals | 65.68x | 81.51% | $7.20B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
